NUCLEOSIDES AS ANTI-ORTHOPOXVIRUS AGENTS
核苷作为抗正痘病毒剂
基本信息
- 批准号:6532839
- 负责人:
- 金额:$ 26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-08-15 至 2004-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (adapted from applicant's abstract): We are proposing a study to
further develop two compound classes as potential antipoxvirus agents. The
leads for our study are carbocyclic 3-deazaadenosine, which has reproducible
and potent in vitro and in vivo anti-vaccinia virus activities, and N1-
aralkyloxyadenosines, which have reproducible and potent in vitro anti-
vaccinia virus activity, but have not yet been examined in vivo. The in vitro
activities for both lead compounds groups were previously discovered in a
USAMRIID compound screen against viruses of interest to the Army, while the in
vivo anti-vaccinia activity has been recently seen in a USAMRIID study of
compounds as potential antipoxvirus agents.
Our efforts toward the proposed carbocyclic 3-deazaadenosine analogues will be
directed toward optimizing both their antipoxvirus activities as well as their
S-adenosylhomocysteine (SAH) hydrolase inhibition. A close relationship has
been noted between these two properties in our lead compound and in a number
of other nucleoside analogues reported in the literature. We will be
targeting new carbocyclic 3-deazaadenosine analogues and other nucleoside
analogues that have a modified 5-prime side chain that can interact with the
hydrophobic and hydrophilic groups in the hydrolase pocket that normally
interact with the homocysteine of S-adenosylhomocysteine. Our pursuit of new
analogues of our N1-aralkyloxyadenosines lacks a mechanistic rationale, and
thus, we will be preparing new analogues with aralkyl (both heterocyclic and
benzylic) and cycloalkyl groups that can help in both the optimization of
their anti-vaccinia activities and the elucidation of the mechanism of action
will be joint focuses.
The synthesis of all of our target compounds will be pursued in SRI. Larger
quantities of any promising leads can also be synthesized in our Prep
laboratories. The design of future targets will be a joint effort between SRI
and our group of collaborators. Dr. John Huggins of USAMRIID, Dr. Ronald T.
Borchardt of the University of Kansas, and Dr. Erik De Clercq of the Rega
Institute in Belgium will be evaluating our compounds for their antipoxvirus
activities and their SAH hydrolase inhibition. Dr. Stewart Shuman of the
Sloan Kettering Research Institute will be helping us by concentrating on the
mechanism of action of the N1-aralkyloxyadenosine analogs.
描述(改编自申请人摘要):我们提出了一项研究,
进一步开发两类化合物作为潜在的抗痘病毒剂。 的
我们研究的先导化合物是碳环3-脱氮腺苷,
和有效的体外和体内抗牛痘病毒活性,以及N1-
芳烷氧基腺苷,其具有可重复的和有效的体外抗-
牛痘病毒活性,但尚未在体内进行检测。 体外
这两种先导化合物组的活性先前在一个
USAMRIID化合物对陆军感兴趣的病毒进行筛选,而
体内抗牛痘活性最近在USAMRIID研究中被观察到,
化合物作为潜在的抗痘病毒剂。
我们的努力对拟议的碳环3-deazaadenosine类似物将是
旨在优化其抗痘病毒活性以及
S-腺苷高半胱氨酸(SAH)水解酶抑制。 亲密的关系
在我们的先导化合物中,
其他核苷类似物的文献报道。 我们将
靶向新的碳环3-脱氮腺苷类似物和其它核苷
具有修饰的5-prime侧链的类似物,其可以与
水解酶口袋中的疏水和亲水基团,
与S-腺苷同型半胱氨酸的同型半胱氨酸相互作用。 我们对新的追求
我们的N1-芳烷氧基腺苷的类似物缺乏机理原理,
因此,我们将制备新的芳烷基类似物(杂环和
苄基)和环烷基,其可以帮助优化
它们的抗牛痘活性及其作用机制的阐明
将是共同的焦点。
我们所有目标化合物的合成将在SRI中进行。 较大
在我们的Prep中也可以合成大量的任何有希望的先导化合物。
laboratories. 未来目标的设计将是SRI和
和我们的合作者 USAMRIID的约翰·哈金斯博士、罗纳德·T.
堪萨斯大学的Borchardt和Rega的Erik De Clercq博士
比利时的研究所将评估我们的化合物用于抗痘病毒
活性及其SAH水解酶抑制。 斯图尔特·舒曼博士
斯隆凯特琳研究所将帮助我们集中精力,
N1-芳烷氧基腺苷类似物的作用机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN A SECRIST其他文献
JOHN A SECRIST的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN A SECRIST', 18)}}的其他基金
4'-Substituted nucleoside analogs as anticancer drugs
4-取代核苷类似物作为抗癌药物
- 批准号:
8212510 - 财政年份:2008
- 资助金额:
$ 26万 - 项目类别:
Drug Design and Synthesis for Orthopoxvirus Infections
正痘病毒感染的药物设计与合成
- 批准号:
7652108 - 财政年份:2008
- 资助金额:
$ 26万 - 项目类别:
4'-Substituted nucleoside analogs as anticancer drugs
4-取代核苷类似物作为抗癌药物
- 批准号:
7464122 - 财政年份:2008
- 资助金额:
$ 26万 - 项目类别:
4'-Substituted nucleoside analogs as anticancer drugs
4-取代核苷类似物作为抗癌药物
- 批准号:
8018541 - 财政年份:2008
- 资助金额:
$ 26万 - 项目类别:
4'-Substituted nucleoside analogs as anticancer drugs
4-取代核苷类似物作为抗癌药物
- 批准号:
7758375 - 财政年份:2008
- 资助金额:
$ 26万 - 项目类别:
4'-Substituted nucleoside analogs as anticancer drugs
4-取代核苷类似物作为抗癌药物
- 批准号:
7585807 - 财政年份:2008
- 资助金额:
$ 26万 - 项目类别:
DESIGN OF NEW NUCLEOSIDES BASED ON ENZYME SPECIFICITIES
基于酶特异性的新核苷设计
- 批准号:
6563806 - 财政年份:2002
- 资助金额:
$ 26万 - 项目类别:
DESIGN OF NEW NUCLEOSIDES BASED ON ENZYME SPECIFICITIES
基于酶特异性的新核苷设计
- 批准号:
6300244 - 财政年份:2000
- 资助金额:
$ 26万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 26万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 26万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 26万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 26万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 26万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 26万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 26万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 26万 - 项目类别: